We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

85 hedge funds and large institutions have $142M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more capital invested

Capital invested by funds: $76M → $142M (+$66.2M)

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

16% more call options, than puts

Call options by funds: $1.9M | Put options by funds: $1.63M

9% more funds holding

Funds holding: 7885 (+7)

Holders
85
Holders Change
+7
Holders Change %
+8.97%
% of All Funds
2.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
30
Reduced
19
Closed
13
Calls
$1.9M
Puts
$1.63M
Net Calls
+$262K
Net Calls Change
+$346K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$24.2M +$1.01M +309,947 +6%
BFA
2
BlackRock Fund Advisors
California
$17.8M +$213K +65,468 +2%
O
3
OrbiMed
New York
$14.4M +$10.1M +3,121,148 New
PC
4
Paulson & Co
New York
$9.68M +$6.81M +2,095,600 New
Invesco
5
Invesco
Georgia
$9.15M +$6.44M +1,979,987 New
BIT
6
BlackRock Institutional Trust
California
$9.09M +$2.32M +713,752 +57%
State Street
7
State Street
Massachusetts
$8.02M +$54.7K +16,816 +1%
Northern Trust
8
Northern Trust
Illinois
$4.62M -$3.58K -1,101 -0.1%
WSA
9
Wall Street Associates
California
$4.04M -$65.7K -20,200 -2%
Morgan Stanley
10
Morgan Stanley
New York
$3.85M -$807K -248,286 -23%
UBS AM
11
UBS AM
Illinois
$2.94M +$8.46K +2,600 +0.4%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$2.92M +$324K +99,572 +19%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$2.64M +$120K +36,887 +7%
TCIM
14
TIAA CREF Investment Management
New York
$1.63M +$42.1K +12,935 +4%
PVI
15
Pura Vida Investments
New York
$1.5M +$243K +74,700 +30%
Charles Schwab
16
Charles Schwab
California
$1.43M +$259K +79,772 +35%
HighTower Advisors
17
HighTower Advisors
Illinois
$1.35M -$886K -272,393 -48%
TSW
18
Thompson Siegel & Walmsley
Virginia
$1.31M -$9.43K -2,900 -1%
BIM
19
BlackRock Investment Management
Delaware
$1.26M +$1.39K +426 +0.2%
Cambridge Investment Research Advisors
20
Cambridge Investment Research Advisors
Iowa
$1.25M -$110K -33,900 -11%
CC
21
Callan Capital
California
$1.21M +$64.6K +19,877 +8%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$1.11M +$348K +107,104 +81%
TMC
23
Trellus Management Company
Florida
$928K +$146K +45,000 +29%
PC
24
Polar Capital
United Kingdom
$846K +$595K +183,119 New
CI
25
Cowen Inc
New York
$832K

SGYP Hedge Fund Activity: Q1 2015 in Review

85 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2015, worth a combined $142M — up 87% from $76M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new SGYP positions and 13 closed out — a net gain of 7 holders — while 30 added to existing stakes and 19 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $10.1M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.15M sold.

  • 85 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2015, up from 78 in Q4 2014.
  • Funds reported $142M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2015, up 87% quarter-over-quarter.
  • 20 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2015 and 13 closed out, a net change of +7 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2015 was OrbiMed, an estimated $10.1M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2015 was Fidelity Investments, an estimated $5.15M sold.

Based on aggregated 13F filings for Q1 2015.